Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

• Status: Not yet recruiting
• Trial end date: 0000-00-00
• Target enrollment: 3000
• Participant gender: Both

Summary

The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib
• Last Updated: 2016-12-05

Criteria

Inclusion Criteria:

• Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

Exclusion Criteria:

• Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information.

• Patients with hypersensitivity to axitinib or to any other component of INLYTA® .

• Patients under 18.

• Pregnant women.